Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Real-world data of adolescents and young adults with acute lymphoblastic leukemia treated with a modified GMALL protocol in India: Treatment outcomes and challenges

Blood (2025) 146 (Supplement 1): 6321.

https://doi.org/10.1182/blood-2025-6321

Published: 2025

Journal Articles

Real-world experience with varnimcabtagene autoleucel (murine CD19 CAR-T) from India: A step towards enhanced patient access with excellent safety and efficacy

Blood (2025) 146 (Supplement 1): 6304.

https://doi.org/10.1182/blood-2025-6304

Published: 2025

Journal Articles

Lentiviral vector transduced autologous CD34+ cells with FVIII transgene for gene therapy of Hemophilia A with history of inhibitors

Blood (2025) 146 (Supplement 1): 6087.

https://doi.org/10.1182/blood-2025-6087

Published: 2025

Journal Articles

Role of fludarabine exposure on post-transplant outcomes in high-risk β-thalassemia patients undergoing allogeneic HCT with thiotepa/ fludarabine/ treosulfan conditioning

Rachel Renji, Aswin PAI, Nayanthara Bijukumar, Ezhilpavai Mohanan, Sujith Karumathil, Uday Kulkarni, John Panetta, Kavitha Lakshmi, Eunice Edison, Aby Abraham, Biju George, Anu Korula, Vikram Mathews, Poonkuzhali Balasubramanian

Blood (2025) 146 (Supplement 1): 2419.

https://doi.org/10.1182/blood-2025-2419

Published: 2025

Journal Articles

Clinico-pathological profile and treatment patterns of immune mediated aplastic anemia in resource constrained settings – an analysis from the aplastic anemia registry of India

Biju George, Arihant Jain, Neeraj Sidharthan, Tuphan Dolai, Rabindra Jena, Chandrakala Shanmukhaiah, Shashikant Apte, Priyanka Samal, Alka Khadwal, Monisha Harimadhavan, Raveen Raj, Rajib De, Dr PRAKAS KUMAR Mandal, Sudha Sethy, Nutan Joshi, Aby Abraham, Pankaj Malhotra, Vikram Mathews

Blood (2025) 146 (Supplement 1): 6253.

https://doi.org/10.1182/blood-2025-6253

Published: 2025

Journal Articles

Higher busulfan cumulative exposure predicts better thalassemia-free survival in patients with beta thalassemia undergoing HCT with busulfan-cyclophosphamide containing conditioning regimen

Poonkuzhali Balasubramanian, Rachel Renji, Jayachitra Aadi, Aswin PAI, Rajesh Nagarajan, Hemamalini Suresh, John Panetta, Kavitha Lakshmi, Eunice Edison, Sujith Karumathil, Aby Abraham, Anu Korula, Uday Kulkarni, Vikram Mathews, Biju George

Blood (2025) 146 (Supplement 1): 4211.

https://doi.org/10.1182/blood-2025-4211

Published: 2025

Journal Articles

Mim8 prophylaxis in adults and adolescents with hemophilia A: 52-week efficacy and safety outcomes from the phase 3 FRONTIER2 study

Steven Lentz, Aby Abraham, Cihan Ay, Anthony Chan, Víctor Jiménez-Yuste, Johannes Oldenburg, Maria Elisa Mancuso, Johnny Mahlangu, Tadashi Matsushita, Lize van Vulpen, Renchi Yang, Amalie Rhode Høgh Nielsen, Ilgiz Rakhmatullin, Pratima Chowdary

Blood (2025) 146 (Supplement 1): 537.

https://doi.org/10.1182/blood-2025-537

Published: 2025

Journal Articles

Impact-CML: Indian multicentric data supporting safe pregnancy and molecular control in women with chronic myeloid leukemia

Suvir Singh, Arihant Jain, Shouriyo Ghosh, Pankaj Malhotra, Alka Khadwal, Srija Biswas, Aby Abraham, Dinesh Bhurani, Reshma Roshan, Parathan Karunakaran, Sadashivudu Gundeti, Chirag Trivedi, Prasanna Samuel, Omprakash Karunamurthy, Jansi Rani, Rajan Kapoor

Blood (2025) 146 (Supplement 1): 2009.

https://doi.org/10.1182/blood-2025-2009

Published: 2025

Journal Articles

Long-term imatinib therapy leads to significant reduction in GFR

Sanjeevan Sharma, Rajan Kapoor, Kundan Mishra, Aby Abraham, Shouriyo Ghosh, Arihant Jain, Pankaj Malhotra, Prashant Parameswaran, Dinesh Bhurani, Sreeraj Vasudevan, Vikram Mathews, Omprakash Karunamurthy, Manju Sengar

Blood (2025) 146 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2025-2005

Published: 2025

Journal Articles

Impact of cancer and therapy on the epigenetic landscapes of normal cells: Describing a novel biomarker in survivorship

Sushil Selvarajan, Uday Kulkarni, Ramachandran Shaji, Aby Abraham, Anu Korula, Sharon Lionel, Ganesh Jammula, Biju George, Saurabh Agarwal, Vikram Mathews

Blood (2025) 146 (Supplement 1): 1730.

https://doi.org/10.1182/blood-2025-1730

Published: 2025

Journal Articles

EASIX d0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis

Aswin Anand Pai, Nieshanth Parthiban, Nayanthara Bijukumar, Rachel Mariam Renji, Manoj A, Sujith Karumathil, Kavitha M Lakshmi, Sushil Selvarajan, Anu Korula, Fouzia NA, Aby Abraham, Alok Srivastava, Vikram Mathews, Biju George, Uday Kulkarni, Poonkuzhali Balasubramanian

Blood (2024) 144 (Supplement 1): 4879.

https://doi.org/10.1182/blood-2024-201901

Published: 2024

Journal Articles

Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)

Palani Hamenth Kumar, Arun Kumar Arunachalam, Mohammed Yasar, Phaneendra Venkateswara Rao Datari, Uday Kulkarni, Sushil Selvarajan, Anu Korula, Aby Abraham, Biju George, Vikram Mathews

Blood (2024) 144 (Supplement 1): 2090.

https://doi.org/10.1182/blood-2024-201902

Published: 2024

Journal Articles

Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis - Need for Dose Intensification

Aswin Anand Pai, John C Panetta, Nayanthara Bijukumar, Rachel Mariam Renji, Manoj A, Agila Jayaraman, Sujith Karumathil, Anu Korula, Sushil Selvarajan, Alok Srivastava, Aby Abraham, Vikram Mathews, Biju George, Uday Kulkarni, Poonkuzhali Balasubramanian

Blood (2024) 144 (Supplement 1): 2150.

https://doi.org/10.1182/blood-2024-203105

Published: 2024

Journal Articles

Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia Α: Final Results from a Phase 1 Clinical Trial

Blood (2024) 144 (Supplement 1): 1052.

https://doi.org/10.1182/blood-2024-202882

Published: 2024

Journal Articles

Dose Optimization of Check-Point Inhibitors: A Comparison of Standard Dose and Low Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma

Chirag Trivedi, Sujith Kumar, Sushil Selvarajan, Sharon Anbumalar Lionel, Anup J Devasia, Fouzia N., Uday Kulkarni, Aby Abraham, Alok Srivastava, Biju George, Vikram Mathews, Anu Korula

Blood (2024) 144 (Supplement 1): 3048.

https://doi.org/10.1182/blood-2024-198979

Published: 2024

Journal Articles

Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study

Allison P. Wheeler, Aby Abraham, Chris Barnes, Renée Brown Frandsen, Kingsley Hampton, Francisco José López Jaime, Camila Martins Mazini Tavares, Keiji Nogami, Jerzy Windyga, Giancarlo Castaman

Blood (2024) 144 (Supplement 1): 2585.

https://doi.org/10.1182/blood-2024-209752

Published: 2024

Journal Articles

Rationalization of Anti-PD-1 Therapy Using Receptor Occupancy Data to Guide Drug Dosing - a Single Arm Phase II Trial Using Immunomodulation in Relapsed/Refractory Hodgkin Lymphoma

Anu Korula, Arun Arunachalam, Uday Kulkarni, Phaneendra Venkateswara Rao Datari, Sumith Mathew, Aswin Anand PAI, Sushil Selvarajan, Fouzia N., Aby Abraham, Biju George, Poonkuzhali Balasubramanian, Vikram Mathews

Blood (2024) 144 (Supplement 1): 647.

https://doi.org/10.1182/blood-2024-201172

Published: 2024

Journal Articles

Prospective Evaluation of a Defined Replacement Protocol for Peri-Operative Hemostasis in Patients with Severe Hemophilia Α with and without Inhibitors on Emicizumab Prophylaxis Undergoing Elective Major Surgeries. (EmiSurg Study)

Blood (2023) 142 (Supplement 1): 5513.

https://doi.org/10.1182/blood-2023-184564

Published: 2023

Journal Articles

Patterns of Care and Outcome in Adolescent and Young Adults (AYA) Lymphomas- a Multicenter HCC (Hematologic Cancer Consortium) Registry Study from India

Lingaraj Nayak, Sushil Selvarajan, Hasmukh Jain, Parathan Karunakaran, Prasanth Ganesan, Jayachandran Perumal Kalaiyarasi, Nikita Mehra, Anu Korula, Uday Kulkarni, Aby Abraham, Alok Parekh, Ritam Joarder, Santhosh Kumar Devadas, Jina Bhattacharyya, Dubashi Biswajit, Vineetha Raghavan, Mobin Paul

Blood (2023) 142 (Supplement 1): 2412.

https://doi.org/10.1182/blood-2023-185774

Published: 2023

Journal Articles

The Effect of Concizumab Prophylaxis on Target Joints, Resolution and Joint Bleeds in Patients With Hemophilia A or B With or Without Inhibitors in Phase 3 Clinical Trials

Giancarlo Castaman, Aby Abraham, Pantep Angchaisuksiri, Laura Villarreal Martinez, Keiji Nogami, Jameela Sathar, Chunduo Shen, Jay Jay Thaung Zaw, Guy Young

Blood (2023) 142 (Supplement 1): 284.

https://doi.org/10.1182/blood-2023-180790

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Real-world data of adolescents and young adults with acute lymphoblastic leukemia treated with a modified GMALL protocol in India: Treatment outcomes and challenges

Real-world experience with varnimcabtagene autoleucel (murine CD19 CAR-T) from India: A step towards enhanced patient access with excellent safety and efficacy

Lentiviral vector transduced autologous CD34+ cells with FVIII transgene for gene therapy of Hemophilia A with history of inhibitors

Role of fludarabine exposure on post-transplant outcomes in high-risk β-thalassemia patients undergoing allogeneic HCT with thiotepa/ fludarabine/ treosulfan conditioning

Clinico-pathological profile and treatment patterns of immune mediated aplastic anemia in resource constrained settings – an analysis from the aplastic anemia registry of India

Higher busulfan cumulative exposure predicts better thalassemia-free survival in patients with beta thalassemia undergoing HCT with busulfan-cyclophosphamide containing conditioning regimen

Mim8 prophylaxis in adults and adolescents with hemophilia A: 52-week efficacy and safety outcomes from the phase 3 FRONTIER2 study

Impact-CML: Indian multicentric data supporting safe pregnancy and molecular control in women with chronic myeloid leukemia

Long-term imatinib therapy leads to significant reduction in GFR

Impact of cancer and therapy on the epigenetic landscapes of normal cells: Describing a novel biomarker in survivorship

EASIX d0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis

Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)

Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis - Need for Dose Intensification

Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia Α: Final Results from a Phase 1 Clinical Trial

Dose Optimization of Check-Point Inhibitors: A Comparison of Standard Dose and Low Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma

Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study

Rationalization of Anti-PD-1 Therapy Using Receptor Occupancy Data to Guide Drug Dosing - a Single Arm Phase II Trial Using Immunomodulation in Relapsed/Refractory Hodgkin Lymphoma

Prospective Evaluation of a Defined Replacement Protocol for Peri-Operative Hemostasis in Patients with Severe Hemophilia Α with and without Inhibitors on Emicizumab Prophylaxis Undergoing Elective Major Surgeries. (EmiSurg Study)

Patterns of Care and Outcome in Adolescent and Young Adults (AYA) Lymphomas- a Multicenter HCC (Hematologic Cancer Consortium) Registry Study from India

The Effect of Concizumab Prophylaxis on Target Joints, Resolution and Joint Bleeds in Patients With Hemophilia A or B With or Without Inhibitors in Phase 3 Clinical Trials

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only